"www.healthbusiness.nl"

Many prescription drugs are valuable in treating diseases for which they were not approved, but doctors, insurers and drug-makers have little to guide them in how to evaluate the safety, efficacy and cost-effectiveness of these drugs in their “off-label” uses.
Lees meer..

This entry was posted on Wednesday, December 10th, 2008 at 10:40 am and is filed under Nieuws, Pharma. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.